1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 13,280 | 13,360 | 11.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period April to June 2025 | 84 | GlobeNewswire (Europe) | "A positive operating result was recorded in the second quarter. The effects of the cost-cutting program initiated at the beginning of the year can already be seen in both current costs and in the cost... ► Artikel lesen | |
| DEVYSER DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 30.06. | Devyser Diagnostics AB: Devyser launches Genomic Blood Typing assay: All blood groups, one simple test | 106 | GlobeNewswire (Europe) | Devyser today announced the global launch of Devyser Genomic Blood Typing, a next-generation sequencing (NGS)-based solution that redefines molecular blood group research. Developed exclusively, this... ► Artikel lesen | |
| 29.04. | Devyser Q1 2025 slides reveal mixed results with 8% growth, EBIT challenges | 1 | Investing.com | ||
| 29.04. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | 362 | GlobeNewswire (Europe) | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen | |
| 14.04. | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | 192 | GlobeNewswire (Europe) | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
| 19.02. | Devyser Diagnostics AB: Devyser secures a major SEK 16.8M tender in Italy with 30% growth | 230 | GlobeNewswire (Europe) | Devyser a leading provider of genetic testing solutions, has been awarded a significant tender for the supply of its comprehensive next-generation sequencing (NGS) tests for critical genetic markers.... ► Artikel lesen | |
| 13.02. | Devyser Diagnostics AB: Devyser Diagnostics AB publishes year-end report for January to December 2024 | 337 | GlobeNewswire (Europe) | "Net sales increased during the fourth quarter by 41.5 percent to SEK 64.2 million, compared with the corresponding quarter of 2023. The growth and strong performance are a result of robust development... ► Artikel lesen | |
| 28.01. | Devyser Diagnostics AB: Devyser wins tender in Italy for its cystic fibrosis NGS test worth up to 5.4 million SEK | 190 | GlobeNewswire (Europe) | Devyser has secured a tender for its cystic fibrosis NGS test, Devyser CFTR. The tender with Policlinico di Bari is valid for five years with an estimated total order value up to 5.4 million SEK
"This... ► Artikel lesen | |
| 16.01. | Devyser Diagnostics AB: Devyser publishes preliminary result for Q4 2024 | 706 | GlobeNewswire (Europe) | In light of this morning's communication that Fredrik Alpsten is leaving his position as CEO of Devyser and to avoid speculation, Devyser is releasing a summary of the year-end report for 2024 before... ► Artikel lesen | |
| 30.10.24 | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period July to September 2024 | 143 | GlobeNewswire (Europe) | "It is very gratifying to see the impact that we are having in the field of diagnostics. I have just returned from the ASHI event, a major transplantation conference in the US, and it is clear that... ► Artikel lesen |
10 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDTRONIC | 80,03 | +0,25 % | Medtronic Diabetes shares preview of new Abbott sensor made for MiniMed insulin delivery systems | ||
| HCA HEALTHCARE | 328,20 | +0,12 % | Leichte Zugewinne bei der HCA-Aktie (318,8134 €) | Im Plus liegt zur Stunde das Wertpapier von HCA . Zuletzt zahlten Investoren für die Aktie 371,00 US-Dollar. Freuen können sich gegenwärtig die Aktionäre von HCA: Das Wertpapier weist derzeit einen... ► Artikel lesen | |
| LANTHEUS | 47,800 | -2,71 % | Pre-market Movers: Myriad Genetics, LifeMD, Evolus, Lantheus Holdings, Astera Labs | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.15 A.M. ET).In the Green Myriad Genetics, Inc. (MYGN) is up over 30% at $5.04.
Astera... ► Artikel lesen | |
| AMEDISYS | 86,00 | -1,15 % | DOJ: UHG, Amedisys Must Divest 164 Locations for Acquisition to Proceed | ||
| ENVISTA | 17,300 | +0,58 % | Envista Holdings Corporation: Envista Reports Second Quarter 2025 Results | BREA, Calif., July 31, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended June 27, 2025.
"Envista achieved... ► Artikel lesen | |
| CAREDX | 10,285 | +0,05 % | CareDx Q2 2025 slides: 14% revenue growth despite analyst miss, EBITDA surges | ||
| SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Third Quarter 2025 Results | Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON... ► Artikel lesen | |
| GT BIOPHARMA | 1,740 | +0,58 % | GT Biopharma, Inc.: GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2 | The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observedThe... ► Artikel lesen | |
| CARMAT | 0,463 | +10,63 % | XFRA CXT: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CHEMOMETEC | 65,80 | -1,57 % | Chemometec A/S: Preliminary revenue figures for the 2024/25 financial year | ANNOUNCEMENT NO. 290 1 July 2025 Preliminary revenue figures for the 2024/25 financial year Based on the preliminary financial figures, ChemoMetec now expects revenue of around DKK 496 million... ► Artikel lesen | |
| POLAREAN IMAGING | 0,001 | 0,00 % | Polarean Imaging PLC - Promotion & sales representative agreement | ||
| ARRAIL GROUP | 0,278 | +1,46 % | ARRAIL GROUP (06639): FORM OF PROXY FOR 2025 ANNUAL GENERAL MEETING | ||
| PROMIMIC | 1,520 | +1,00 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
| FRESENIUS | 43,800 | +0,14 % | Fresenius vor Zahlen: Darauf kommt es an | Am morgigen Mittwoch (06. August) wird der Gesundheitskonzern Fresenius die Zahlen für das abgelaufene zweite Quartal 2025 vorlegen. DER AKTIONÄR zeigt auf, was die Analysten vom Bad Homburger Unternehmen... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,460 | +0,75 % | FMC-CFO Martin Fischer - "Wir werden zuverlässig liefern" | Nach dem Kapitalmarkttag Mitte Juni waren bei Analysten Zweifel aufgekommen, ob Fresenius Medical Care die bis 2030 versprochene Margenverbesserung tatsächlich erreichen kann. Im exklusiven Interview... ► Artikel lesen |
Das Unternehmen DEVYSER DIAGNOSTICS AB kann der Branche Gesundheitswesen zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,080 (+0,61 %) liegt der Kurs bei 13,280 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DEVYSER DIAGNOSTICS AB finden Sie auf Wallstreet Online.